SENORES Senores Pharmaceuticals Q4 FY26 results (Jan–Mar 2026) and concall
Senores Pharmaceuticals Limited reported a robust Q4 and FY26 performance, with FY26 revenue growing 62% to INR 664 crores and PAT increasing 108% to INR 122 crores, surpassing guidance. The company significantly expanded its ANDA portfolio to 51 approvals and made strategic acquisitions like Apnar Pharma and Zoraya Pharmaceuticals to strengthen its US presence. Despite a conservative outlook for FY27 revenue growth of 30-40% and PAT growth of 50-60% due to external uncertainties, the company remains optimistic about its product pipeline and manufacturing capacities.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 53.5%, net profit up 105.6% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 101 | 103 | 114 | 138 | 162 +60% | 171 +66% | 175 +54% |
| EBITDA | 23 | 26 | 19 | 34 | 50 +117% | 50 +92% | 47 +147% |
| Net profit | 13 | 16 | 18 | 21 | 30 +131% | 34 +113% | 37 +106% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
